The study began with 219 patients, but after excluding certain individuals, the researchers narrowed the final count to 198, with 69 in placebo. They ultimately concluded that while longer follow-up is required, their findings suggest that the pills are an affordable intervention for chemotherapy-induced thrombocytopenia (low platelet count) and may help maintain chemotherapy intensity.